Document Detail


Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry.
MedLine Citation:
PMID:  18317669     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: Drug-eluting stents have been reported to effectively reduce in-stent restenosis (ISR). However, the effectiveness and safety have yet been investigated only in small trials or case series. The aim of this prospective large scale registry was to show that treatment of ISR with sirolimus eluting stents (SES) is safe, effective and feasible in daily routine. METHODS AND RESULTS: The German Cypher registry prospectively enrolled 6,555 patients undergoing implantation with SES for various indications, including 1,533 patients treated for ISR. Follow-up data (median 6.6 months) of this cohort was available for 1,531 patients (99.8%). Of these patients 75.8% were male. Of these patients 36.5% (n = 552) presented with acute coronary syndromes. In total, 1,932 SES were used with successful implantation in 98.9%. MI during hospitalization was observed in 0.7% (n = 11) while in-hospital mortality was only 0.1% (n = 2). MACE-rate at follow-up was 13.8% (n = 211) including a mortality of 1.3% (n = 20) and MI in 1.9% (n = 29). Total revascularization procedures including CABG (1.7%) were necessary in 12.3% (n = 186). Target vessel revascularization (TVR) rate was 9.3% (n = 139) and thus similar to patients with de novo lesions (8.1%, P = 0.69). Ten patients (0.65%) suffered from subacute stent thrombosis Vs. 0.24% observed in patients with de novo lesions (P = 0.03). CONCLUSION: This large registry confirms that treatment of ISR with sirolimus-eluting-stents is effective and save with good clinical results at index procedure and follow-up. TVR was not different from de novo lesions.
Authors:
Helge Möllmann; Albrecht Elsässer; Holger Nef; Steffen Schneider; Christoph A Nienaber; Gert Richardt; Michael Weber; Malte Kelm; Benny Levenson; Tassilo Bonzel; Ulrich Tebbe; Georg Sabin; Thomas Pfannebecker; Jochen Senges; Christian W Hamm
Related Documents :
17441309 - Comparison of short- and long-term outcomes between cypher and taxus drug-eluting stent...
21584199 - High flexion total knee arthroplasty - mid-term follow up of 5 years.
23521659 - Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infl...
11721719 - Increased reperfusion by glycoprotein iib/iiia receptor antagonist administration in ca...
16282539 - Drug-eluting stents for the treatment of intracranial atherosclerosis: initial experien...
24107579 - Physical performance and frailty in chronic kidney disease.
21358799 - Evaluation of bachmann bundle pacing versus right atrial pacing in prevention of atrial...
18596309 - Impact of high-dose antioxidants on outcomes in acutely injured patients.
24882459 - Recovery of vocal fold immobility following isolated patent ductus arteriosus ligation.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2008-03-03
Journal Detail:
Title:  Clinical research in cardiology : official journal of the German Cardiac Society     Volume:  97     ISSN:  1861-0692     ISO Abbreviation:  -     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-16     Completed Date:  2009-01-12     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101264123     Medline TA:  Clin Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  432-40     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Kerckhoff Heart Centre, Bad Nauheim, Germany. h.moellmann@kerckhoff-klinik.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Drug-Eluting Stents*
Feasibility Studies
Female
Follow-Up Studies
Germany / epidemiology
Graft Occlusion, Vascular / epidemiology,  mortality,  therapy*
Hospital Mortality
Humans
Immunosuppressive Agents / therapeutic use*
Male
Middle Aged
Prospective Studies
Registries*
Sirolimus / therapeutic use*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Risk predictors for adverse outcomes after percutaneous coronary interventions and their related cos...
Next Document:  A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple s...